Announcements Trials
Browse Landscape

Phase

Phase NA 32Phase 4 3Phase 3 3Phase 2/3 3Phase 2 3Phase 1/2 2

Status

Completed 7Unknown 3Recruiting 2Withdrawn 1Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Weight Loss 1Protein Deficiency 1Prolactinoma 1Neoplasms 1Malnutrition 1

Interventions

Metformin 16Cyclophosphamide 16Drug Therapy 14Dexamethasone 14Cisplatin 13Cytarabine 11Gemcitabine 10Radiotherapy 9Oxaliplatin 9Carboplatin 9Vincristine 8Paclitaxel 8Idarubicin 8Etoposide 8Docetaxel 8ulipristal acetate 7icotinib 7Sodium Chloride 7Methotrexate 7Fluorouracil 7Dexmedetomidine 7entecavir 6Thalidomide 6Surgical Procedures, Operative 6Sorafenib 6Pemetrexed 6Leuprolide 6Granulocyte Colony-Stimulating Factor 6Epirubicin 6Doxorubicin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 4 × Unknown × Standard of Care × Clear all
NCT04687124 2020-12-29

EPA Supplementation in Cancer Patients Receiving Abdominal Radiotherapy -

University of Copenhagen

Phase 4 Unknown
26 enrolled

Protein Deficiency, Weight Loss, Malnutrition

NCT04107480 2020-07-20

PRolaCT - Three Prolactinoma RCTs

Leiden University Medical Center

Phase 4 Unknown
880 enrolled

Prolactinoma

NCT03831633 2019-02-06

Comparative Effectiveness of AKYNZEO® and Standard of Care (Including EMEND®) for the Prevention of Nausea and Vomiting (CINV) in Cancer Patients

VIFORFRANCE

Phase 4 Unknown
426 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡